Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the February 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

For BIIB (NASDAQ:BIIB), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $145.00 strike.

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...

$50,000 of BIOGEN INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. BIIB insiders have traded $BIIB stock on the open market ...

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...

(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...